The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC).
Lipika Goyal
No relevant relationships to disclose
Darrell R. Borger
Consultant or Advisory Role - Bio-Reference Laboratories; Snapshot
Thomas Yau
No relevant relationships to disclose
Ronnie Tung Ping Poon
No relevant relationships to disclose
Marek Ancukiewicz
No relevant relationships to disclose
David C. Christiani
No relevant relationships to disclose
Hannah M. Liebman
No relevant relationships to disclose
Katharine Yen
Employment or Leadership Position - Agios
Stock Ownership - Agios
Kimberly Straley
Employment or Leadership Position - Agios
Samuel V. Agresta
Employment or Leadership Position - Agios
Jason Edward Faris
No relevant relationships to disclose
Eunice Lee Kwak
No relevant relationships to disclose
Jeffrey W. Clark
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
Kenneth Tanabe
No relevant relationships to disclose
Vikram Deshpande
No relevant relationships to disclose
Rakesh K. Jain
No relevant relationships to disclose
Anthony John Iafrate
No relevant relationships to disclose
Dan G. Duda
No relevant relationships to disclose
Andrew X. Zhu
No relevant relationships to disclose